SCRT VS LCRT Followed by PD-L1 Inhibitor Plus CAPEOX as TNT in Patients With LARC

SCRT VS LCRT Followed by PD-L1 Inhibitor Plus CAPEOX as TNT in Patients With LARC is a phase 2, randomised interventional study registered as NCT07284992 by Shandong Provincial Hospital, with a registry enrolment figure of 208 participants, started 2025-09-12 and due to reach its primary completion in 2028-11-30. Interventions recorded: short-term radiotherapy combined with Adebrelimab and capox; long-term radiotherapy combined with Adebrelimab and capox. Conditions listed: Rectal Cancer; Advanced Stage Colorectal Cancer; Radiotherapy. Primary outcome: CR rate. Colorectal eligibility wording from the registry: "Patients diagnosed as rectal adenocarcinoma by primary biopsy and histopathological examination;". Sites: China. No results are recorded here; the registry entry is the source.